Drug Development · us
PAS-004 Cleared for Phase 2 Trial Exploring Oral Treatment for NF1 Cutaneous Neurofibromas
Benign tumors on the skin can also create a burden that lasts for years. Pasithea announced that it has received clearance from the U.S. FDA to test PAS-004 in a placebo-controlled study; whether it can improve lesions and be suitable for long-term use remains to be answered by human data.
For patients with neurofibromatosis type 1 (NF1), the gradual increase in tumors on the skin can place long-term pressure on appearance, social interactions, and daily life. Current management largely relies on removing lesions individually. Whether oral medication can offer another option is a pressing question for treatment research.
Pasithea Therapeutics announced on November 3 that the U.S. Food and Drug Administration (FDA) has cleared its investigational drug PAS-004 to enter a randomized, placebo-controlled Phase 2 clinical trial for NF1-associated cutaneous neurofibromas (cNF). This IND clearance allows the study to proceed; it does not mean the drug has been approved for marketing or that its efficacy has been established.
Cutaneous neurofibromas are benign lesions that often begin appearing during puberty and may increase in number and size with age. Surgery, lasers, and other methods can treat individual tumors, but when lesions are widespread, the treatment burden also increases. According to the company's announcement, there is currently no FDA-approved systemic drug treatment for this indication.
PAS-004 is an oral macrocyclic MEK inhibitor. The company aims to develop it as a long-term treatment with once-daily dosing and cites its longer half-life and more stable blood concentrations as design advantages. However, whether these properties can translate into acceptable long-term tolerability and clinical benefit still needs to be demonstrated in trials.
There is precedent for MEK inhibitors in NF1 treatment, but the lesion types must be distinguished. The FDA has approved mirdametinib for certain patients with symptomatic NF1-associated plexiform neurofibromas that cannot be completely resected. That indication differs from the cutaneous neurofibromas being studied here, and the existing approval cannot be directly regarded as evidence of efficacy for PAS-004 or for cutaneous lesions.
The announcement did not disclose the Phase 2 trial's enrollment target, doses, primary endpoints, or timeline for results, and no efficacy data from this trial are yet available. The placebo-controlled design will help clarify the treatment effect. For patients who may need long-term medication, key considerations in assessing its value will also include whether improvements in lesions are accompanied by better quality of life, and the burden of side effects associated with continued treatment.